Campbell B, Shin Y K, Scalia R, Lefer A M
Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Cardiovasc Res. 1998 Aug;39(2):393-400. doi: 10.1016/s0008-6363(98)00116-3.
Ischemia followed by reperfusion in the presence of polymorphonuclear leukocytes (PMNs) results in cardiac contractile dysfunction as well as myocardial injury. These deleterious effects are due in large part to endothelial dysfunction leading to an upregulation of cell adhesion molecules and subsequent neutrophil-induced cardiac injury. At physiologically relevant concentrations, N,N,N-trimethylsphingosine (TMS), a synthetic N-methylated sphingosine derivative, has been shown to attenuate leukocyte-endothelial cell interactions. We wanted to test the effects of TMS on neutrophil-mediated cardiac dysfunction in ischemia/reperfusion.
This study examines the effects of TMS in a neutrophil-dependent isolated perfused rat heart model of ischemia (I) (20 min) and reperfusion (R) (45 min) injury.
Administration of TMS (20 micrograms/kg) to I/R hearts perfused with PMNs improved coronary flow and preserved left ventricular developed pressure as an index of cardiac contractile function (95 +/- 5%) in comparison to those I/R hearts receiving only vehicle (60 +/- 7%) (P < 0.001). In addition, TMS significantly reduced PMN accumulation in the ischemic myocardium, as evidenced by an attenuation in cardiac myeloperoxidase activity from 1.12 +/- 0.04 in untreated hearts to 0.01 +/- 0.02 in treated hearts (P < 0.001). However, TMS did not directly stimulate nitric oxide (NO) release from rat vascular endothelium.
These results provide evidence that TMS is a potent and effective cardioprotective agent that inhibits leukocyte-endothelial cell interactions and preserves cardiac contractile function and coronary perfusion following myocardial ischemia and reperfusion.
在多形核白细胞(PMN)存在的情况下,缺血后再灌注会导致心脏收缩功能障碍以及心肌损伤。这些有害影响在很大程度上归因于内皮功能障碍,导致细胞黏附分子上调以及随后中性粒细胞诱导的心脏损伤。在生理相关浓度下,N,N,N-三甲基鞘氨醇(TMS),一种合成的N-甲基化鞘氨醇衍生物,已被证明可减弱白细胞与内皮细胞的相互作用。我们想要测试TMS对缺血/再灌注过程中中性粒细胞介导的心脏功能障碍的影响。
本研究考察了TMS在中性粒细胞依赖性离体灌注大鼠心脏缺血(I)(20分钟)和再灌注(R)(45分钟)损伤模型中的作用。
与仅接受赋形剂的缺血/再灌注心脏相比(60±7%),向灌注有PMN的缺血/再灌注心脏给予TMS(20微克/千克)可改善冠脉血流,并保留左心室舒张末压作为心脏收缩功能的指标(95±5%)(P<0.001)。此外,TMS显著减少了缺血心肌中PMN的积聚,这可通过心脏髓过氧化物酶活性从未处理心脏的1.12±0.04减弱至处理心脏的0.01±0.02来证明(P<0.001)。然而,TMS并未直接刺激大鼠血管内皮释放一氧化氮(NO)。
这些结果提供了证据,表明TMS是一种有效的心脏保护剂,可抑制白细胞与内皮细胞的相互作用,并在心肌缺血和再灌注后保留心脏收缩功能和冠脉灌注。